AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 21 min read$GILD

O'Day Daniel Patrick sold $2.2M of GILD

O'Day Daniel Patrick (Chairman & CEO) sold 15,000 shares of GILEAD SCIENCES, INC. (GILD) at an average of $147.90 ($147.72–$148.63, $2.22M total) across 2 trades on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · O'Day Daniel Patrick
Published Oct 2, 2026, 8:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 8:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GILD
Bearish
high confidence
Mentioned
$GILD
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GILDBearishLow
01

Why it matters

The disclosed sale may trigger short‑term selling pressure, but the long‑term impact depends on GILD's pipeline and earnings outlook.

02

Market read

Insider sales by top executives are closely watched; this filing provides fresh data that could affect short‑term trading decisions.

03

What to watch

Potential upcoming FDA decisions or pipeline news may be the real driver of price movement.

Relevance 5/10Novelty 6/10Timing: pre‑market tomorrow

Background

Form 4 filings disclose insider transactions; a CEO sale of $2.2M is noteworthy for investors monitoring insider activity.

Company-level read

Ticker impact

$GILDBearishHigh confidence
Context

CEO Daniel O'Day sold 15,000 shares for $2.2M via a 10b5‑1 plan, reducing his stake to 566,683 shares.

Expected impact

likely downward pressure as the market prices the insider sell.

Evidence & confidence

A senior executive sold a multi‑million dollar position; such sales are typically viewed as bearish by traders.

Market effects

Sector

Minimal impact on the broader biotech sector; the sale is company‑specific.

Regional

U.S. market only; no regional ripple effect.

Global

Limited global relevance beyond GILD investors.

Counterpoint

What could challenge this read

The sale could be routine under a 10b5‑1 plan and not reflect negative sentiment.

Key entities

  • Company
    Gilead Sciences, Inc.

    Biopharmaceutical company whose CEO sold shares.

  • Executive
    Daniel O'Day

    Chairman & CEO of Gilead Sciences.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GILD insider trading history →

Related articles

OCT 16
$GILDMed

5 Breast Cancer Advances in 2026—And The Questions They Leave Unanswered

The FDA approved several breast cancer treatments in 2026, including Daiichi Sankyo's fam-trastuzumab deruxtecan for early-stage HER2-positive breast cancer, datopotamab deruxtecan for triple-negative breast cancer, Gilead Sciences' sacituzumab govitecan for first-line TNBC, Pfizer's palbociclib for maintenance therapy, and AstraZeneca's camizestrant for HR-positive, HER2-negative advanced breast cancer.

pharmacytimes.com5 min
OCT 15
$GILDHighAI 9/10

Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers

Gilead Sciences and Vir Biotechnology agreed to collaborate on developing T-cell engager therapies for solid tumors. Gilead will pay $90m upfront, including $65m in cash and $25m in equity, with up to $1.74bn in potential milestones. Gilead will lead development and commercialization, using Vir's PRO-XTEN technology and AI platform. This follows their 2021 hepatitis B drug collaboration and Vir's recent deal with Astellas.

finance.yahoo.com2 min
OCT 14
$VIRHighAI 9/10

Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal

Vir Biotechnology and Gilead Sciences agreed to collaborate on cancer therapies for solid tumors, with a deal potentially worth up to $1.88 billion. Vir will receive $90 million upfront and could earn additional milestone payments and royalties. The partnership focuses on developing three drug candidates using Vir's technologies. Vir shares rose over 10% in premarket trading.

finance.yahoo.com2 min
OCT 14
$VIRHighAI 8/10

Vir Biotechnology partners with Gilead on cancer therapies

Vir Biotechnology (VIR) and Gilead Sciences (GILD) announced a collaboration to develop cancer therapies. VIR will receive $90M upfront, with potential milestones up to $1.74B. VIR will handle discovery, while GILD will develop and commercialize the therapies. The deal focuses on T-cell engagers targeting solid tumors.

investing.com2 min